<b>Objective</b>  The aim of this study was to explore an innovative approach for developing deep learning (DL) algorithm for renal cell carcinoma (RCC) detection and subtyping on computed tomography (CT): clear cell RCC (ccRCC) versus non-ccRCC using two-dimensional (2D) neural network architecture and feature consistency modules. <b>Materials and Methods</b>  This retrospective study included baseline CT scans from 196 histopathologically proven RCC patients: 143 ccRCCs and 53 non-ccRCCs. Manual tumor annotations were performed on axial slices of corticomedullary phase images, serving as ground truth. After image preprocessing, the dataset was divided into training, validation, and testing subsets. The study tested multiple 2D DL architectures, with the FocalNet-DINO demonstrating highest effectiveness in detecting and classifying RCC. The study further incorporated spatial and class consistency modules to enhance prediction accuracy. Models' performance was evaluated using free-response receiver operating characteristic curves, recall rates, specificity, accuracy, F1 scores, and area under the curve (AUC) scores. <b>Results</b>  The FocalNet-DINO architecture achieved the highest recall rate of 0.823 at 0.025 false positives per image (FPI) for RCC detection. The integration of spatial and class consistency modules into the architecture led to 0.2% increase in recall rate at 0.025 FPI, along with improvements of 0.1% in both accuracy and AUC scores for RCC classification. These enhancements allowed detection of cancer in an additional 21 slices and reduced false positives in 126 slices. <b>Conclusion</b>  This study demonstrates high performance for RCC detection and classification using DL algorithm leveraging 2D neural networks and spatial and class consistency modules, to offer a novel, computationally simpler, and accurate DL approach to RCC characterization.

Purpose To assess the agreement between routine-dose (RD) and lower-dose (LD) contrast-enhanced CT scans, with and without Digital Imaging and Communications in Medicine-based deep learning-based denoising (DLD), in evaluating small renal masses (SRMs) during active surveillance. Materials and Methods In this retrospective study, CT scans from patients undergoing active surveillance for an SRM were included. Using a validated simulation technique, LD CT images were generated from the RD images to simulate 75% (LD75) and 90% (LD90) radiation dose reductions. Two additional LD image sets, in which the DLD was applied (LD75-DLD and LD90-DLD), were generated. Between January 2023 and June 2024, nine radiologists from three institutions independently evaluated 350 CT scans across five datasets for tumor size, tumor nearness to the collecting system (TN), and tumor shape irregularity (TSI), and interobserver reproducibility and agreement were assessed using the 95% limits of agreement with the mean (LOAM) and Gwet AC2 coefficient, respectively. Subjective and quantitative image quality assessments were also performed. Results The study sample included 70 patients (mean age, 73.2 years ± 9.2 [SD]; 48 male, 22 female). LD75 CT was found to be in agreement with RD scans for assessing SRM diameter, with a LOAM of ±2.4 mm (95% CI: 2.3, 2.6) for LD75 compared with ±2.2 mm (95% CI: 2.1, 2.4) for RD. However, a 90% dose reduction compromised reproducibility (LOAM ±3.0 mm; 95% CI: 2.8, 3.2). LD90-DLD preserved measurement reproducibility (LOAM ±2.4 mm; 95% CI: 2.3, 2.6). Observer agreement was comparable between TN and TSI assessments across all image sets, with no statistically significant differences identified (all comparisons <i>P</i> ≥ .35 for TN and <i>P</i> ≥ .02 for TSI; Holm-corrected significance threshold, <i>P</i> = .013). Subjective and quantitative image quality assessments confirmed that DLD effectively restored image quality at reduced dose levels: LD75-DLD had the highest overall image quality, significantly lower noise, and improved contrast-to-noise ratio compared with RD (<i>P</i> < .001). Conclusion A 75% reduction in radiation dose is feasible for SRM assessment in active surveillance using CT with a conventional iterative reconstruction technique, whereas applying DLD allows submillisievert dose reduction. <b>Keywords:</b> CT, Urinary, Kidney, Radiation Safety, Observer Performance, Technology Assessment <i>Supplemental material is available for this article.</i> © RSNA, 2025 See also commentary by Muglia in this issue.

To develop a deep learning model based on high-frequency ultrasound images to classify different stages of liver fibrosis in chronic hepatitis B patients. This retrospective multicentre study included chronic hepatitis B patients who underwent both high-frequency and low-frequency liver ultrasound examinations between January 2014 and August 2024 at six hospitals. Paired images were employed to train the HF-DL and the LF-DL models independently. Three binary tasks were conducted: (1) Significant Fibrosis (S0-1 vs. S2-4); (2) Advanced Fibrosis (S0-2 vs. S3-4); (3) Cirrhosis (S0-3 vs. S4). Hepatic pathological results constituted the ground truth for algorithm development and evaluation. The diagnostic value of high-frequency and low-frequency liver ultrasound images was compared across commonly used CNN networks. The HF-DL model performance was compared against the LF-DL model, FIB-4, APRI, and with SWE (external test set). The calibration of models was plotted. The clinical benefits were calculated. Subgroup analysis for patients with different characteristics (BMI, ALT, inflammation level, alcohol consumption level) was conducted. The HF-DL model demonstrated consistently superior diagnostic performance across all stages of liver fibrosis compared to the LF-DL model, FIB-4, APRI and SWE, particularly in classifying advanced fibrosis (0.93 [95% CI 0.90-0.95], 0.93 [95% CI 0.89-0.96], p < 0.01). The HF-DL model demonstrates significantly improved performance in both target patient detection and negative population exclusion. The HF-DL model based on high-frequency ultrasound images outperforms other routinely used non-invasive modalities across different stages of liver fibrosis, particularly in advanced fibrosis, and may offer considerable clinical value.

Cone-beam computed tomography (CBCT) for image-guided radiotherapy (IGRT) during liver stereotactic ablative radiotherapy (SABR) is degraded by respiratory motion artefacts, potentially jeopardising treatment accuracy. Mechanically assisted non-invasive ventilation-induced breath-hold (MANIV-BH) can reduce these artefacts. This study compares MANIV-BH and free-breathing CBCTs regarding image quality, IGRT variability, automatic registration accuracy, and deep-learning auto-segmentation performance. Liver SABR CBCTs were presented blindly to 14 operators: 25 patients with FB and 25 with MANIV-BH. They rated CBCT quality and IGRT ease (rigid registration with planning CT). Interoperator IGRT variability was compared between FB and MANIV-BH. Automatic gross tumour volume (GTV) mapping accuracy was compared using automatic rigid registration and image-guided deformable registration. Deep-learning organ-at-risk (OAR) auto-segmentation was rated by an operator, who recorded the time dedicated for manual correction of these volumes. MANIV-BH significantly improved CBCT image quality ("Excellent"/"Good": 83.4 % versus 25.4 % with FB, p < 0.001), facilitated IGRT ("Very easy"/"Easy": 68.0 % versus 38.9 % with FB, p < 0.001), and reduced IGRT variability, particularly for trained operators (overall variability of 3.2 mm versus 4.6 mm with FB, p = 0.010). MANIV-BH improved deep-learning auto-segmentation performance (80.0 % rated "Excellent"/"Good" versus 4.0 % with FB, p < 0.001), and reduced median manual correction time by 54.2 % compared to FB (p < 0.001). However, automatic GTV mapping accuracy was not significantly different between MANIV-BH and FB. In liver SABR, MANIV-BH significantly improves CBCT quality, reduces interoperator IGRT variability, and enhances OAR auto-segmentation. Beyond being safe and effective for respiratory motion mitigation, MANIV increases accuracy during treatment delivery, although its implementation requires resources.

Machine learning identifies liver fat fraction (FF) measured by ¹H MR spectroscopy, insulinemia, and elastography as robust, non-invasive biomarkers for diagnosing steatohepatitis in liver transplant patients, validated through decision tree analysis. Compared to the general population (~5.8% prevalence), MASH is significantly more common in liver transplant recipients (~30%-50%). In patients with FF > 5.3%, the positive predictive value for MASH ranged up to 97%, more than twice the value observed in the general population.

The intertumoral and intratumoral heterogeneity of colorectal adenocarcinoma (CRC) at the morphologic level is poorly understood. Previously, we identified morphological patterns associated with CRC molecular subtypes and their distinct molecular motifs. Here we aimed to evaluate the heterogeneity of these patterns across CRC. Three pathologists evaluated dominant, secondary, and tertiary morphology on four sections from four different FFPE blocks per tumor in a pilot set of 22 CRCs. An AI-based image analysis tool was trained on these tumors to evaluate the morphologic heterogeneity on an extended set of 161 stage I-IV primary CRCs (n = 644 H&E sections). We found that most tumors had two or three different dominant morphotypes and the complex tubular (CT) morphotype was the most common. The CT morphotype showed no combinatorial preferences. Desmoplastic (DE) morphotype was rarely dominant and rarely combined with other dominant morphotypes. Mucinous (MU) morphotype was mostly combined with solid/trabecular (TB) and papillary (PP) morphotypes. Most tumors showed medium or high heterogeneity, but no associations were found between heterogeneity and clinical parameters. A higher proportion of DE morphotype was associated with higher T-stage, N-stage, distant metastases, AJCC stage, and shorter overall survival (OS) and relapse-free survival (RFS). A higher proportion of MU morphotype was associated with higher grade, right side, and microsatellite instability (MSI). PP morphotype was associated with earlier T- and N-stage, absence of metastases, and improved OS and RFS. CT was linked to left side, lower grade, and better survival in stage I-III patients. MSI tumors showed higher proportions of MU and TB, and lower CT and PP morphotypes. These findings suggest that morphological shifts accompany tumor progression and highlight the need for extensive sampling and AI-based analysis. In conclusion, we observed unexpectedly high intratumoral morphological heterogeneity of CRC and found that it is not heterogeneity per se, but the proportions of morphologies that are associated with clinical outcomes.

To review the current risk and prognostic stratification systems in localised prostate cancer. To explore some of the most promising adjuncts to clinical models and what the evidence has shown regarding their value. There are many new biomarker-based models seeking to improve, optimise or replace clinical models. There are promising data on the value of MRI, radiomics, genomic classifiers and most recently artificial intelligence tools in refining stratification. Despite the extensive literature however, there remains uncertainty on where in pathways they can provide the most benefit and whether a biomarker is most useful for prognosis or predictive use. Comparisons studies have also often overlooked the fact that clinical models have themselves evolved and the context of the baseline used in biomarker studies that have shown superiority have to be considered. For new biomarkers to be included in stratification models, well designed prospective clinical trials are needed. Until then, there needs to be caution in interpretation of their use for day-to-day decision making. It is critical that users balance any purported incremental value against the performance of the latest clinical classification and multivariate models especially as the latter are cost free and widely available.

Steatotic liver disease (SLD) is the most common liver disease worldwide, affecting 30% of the global population. It is strongly associated with the interplay of genetic and lifestyle-related risk factors. The genetic variant accounting for the largest fraction of SLD heritability is PNPLA3 I148M, which is carried by 23% of the western population and increases the risk of SLD two to three-fold. However, identification of variant carriers is not part of routine clinical care and prevents patients from receiving personalised care. We analysed MRI images and common genetic variants in PNPLA3, TM6SF2, MTARC1, HSD17B13 and GCKR from a cohort of 45 603 individuals from the UK Biobank. Proton density fat fraction (PDFF) maps were generated using a water-fat separation toolbox, applied to the magnitude and phase MRI data. The liver region was segmented using a U-Net model trained on 600 manually segmented ground truth images. The resulting liver masks and PDFF maps were subsequently used to calculate liver PDFF values. Individuals with (PDFF ≥ 5%) and without SLD (PDFF < 5%) were selected as the study cohort and used to train and test a Vision Transformer classification model with five-fold cross validation. We aimed to differentiate individuals who are homozygous for the PNPLA3 I148M variant from non-carriers, as evaluated by the area under the receiver operating characteristic curve (AUROC). To ensure a clear genetic contrast, all heterozygous individuals were excluded. To interpret our model, we generated attention maps that highlight the regions that are most predictive of the outcomes. Homozygosity for the PNPLA3 I148M variant demonstrated the best predictive performance among five variants with AUROC of 0.68 (95% CI: 0.64-0.73) in SLD patients and 0.57 (95% CI: 0.52-0.61) in non-SLD patients. The AUROCs for the other SNPs ranged from 0.54 to 0.57 in SLD patients and from 0.52 to 0.54 in non-SLD patients. The predictive performance was generally higher in SLD patients compared to non-SLD patients. Attention maps for PNPLA3 I148M carriers showed that fat deposition in regions adjacent to the hepatic vessels, near the liver hilum, plays an important role in predicting the presence of the I148M variant. Our study marks novel progress in the non-invasive detection of homozygosity for PNPLA3 I148M through the application of deep learning models on MRI images. Our findings suggest that PNPLA3 I148M might affect the liver fat distribution and could be used to predict the presence of PNPLA3 variants in patients with fatty liver. The findings of this research have the potential to be integrated into standard clinical practice, particularly when combined with clinical and biochemical data from other modalities to increase accuracy, enabling easier identification of at-risk individuals and facilitating the development of tailored interventions for PNPLA3 I148M-associated liver disease.

Stereotactic magnetic resonance guided adaptive radiation therapy (SMART) is a new option for local treatment of unresectable pancreatic ductal adenocarcinoma, showing interesting survival and local control (LC) results. Despite this, some patients will experience early local and/or metastatic recurrence leading to death. We aimed to develop multiparametric prognostic models for these patients. All patients treated in our institution with SMART for an unresectable pancreatic ductal adenocarcinoma between October 21, 2019, and August 5, 2022 were included. Several initial clinical characteristics as well as dosimetric data of SMART were recorded. Radiomics data from 0.35-T simulation magnetic resonance imaging were extracted. All these data were combined to build prognostic models of overall survival (OS) and LC using machine learning algorithms. Eighty-three patients with a median age of 64.9 years were included. A majority of patients had a locally advanced pancreatic cancer (77%). The median OS was 21 months after SMART completion and 27 months after chemotherapy initiation. The 6- and 12-month post-SMART OS was 87.8% (IC95%, 78.2%-93.2%) and 70.9% (IC95%, 58.8%-80.0%), respectively. The best model for OS was the Cox proportional hazard survival analysis using clinical data, with a concordance index inverse probability of censoring weighted of 0.87. Tested on its 12-month OS prediction capacity, this model had good performance (sensitivity 67%, specificity 71%, and area under the curve 0.90). The median LC was not reached. The 6- and 12-month post-SMART LC was 92.4% [IC95%, 83.7%-96.6%] and 76.3% [IC95%, 62.6%-85.5%], respectively. The best model for LC was the component-wise gradient boosting survival analysis using clinical and radiomics data, with a concordance index inverse probability of censoring weighted of 0.80. Tested on its 9-month LC prediction capacity, this model had good performance (sensitivity 50%, specificity 97%, and area under the curve 0.78). Combining clinical and radiomics data in multiparametric prognostic models using machine learning algorithms showed good performance for the prediction of OS and LC. External validation of these models will be needed.